The MOSAIC Study will evaluate whether an oral drug works to
prevent menstrual migraine attacks.
The study will involve 13 study visits over the course of up to 84 weeks. There is a screening period (up to 16 weeks) to determine if you qualify for the study. Once enrolled in the initial study treatment period (up to 16 weeks), participants will be randomly assigned to 1 of 2 groups and will receive either the active study drug or a placebo (a substance that looks like the study drug but contains no active ingredients), both taken orally (by mouth) for 7 consecutive days in each menstrual cycle.
Those who complete the initial study treatment period may then be able to enroll in a study extension period, which will last for 1 year. All participants will receive the active study drug during this period.
